封面
市場調查報告書
商品編碼
1807167

獸醫抗感染藥物市場-全球產業規模、佔有率、趨勢、機會和預測,按動物類型、產品、給藥途徑、配銷通路、地區和競爭情況細分,2020 年至 2030 年

Veterinary Anti-infectives Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Animal Type, By Product, By Route of Administration, By Distribution Channel, By Region and Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球獸用抗感染藥物市場價值為 83.7 億美元,預計到 2030 年將達到 122 億美元,複合年成長率為 6.45%。隨著牲畜和伴侶動物數量的持續成長,對有效疾病預防和治療解決方案的需求不斷增加,全球獸用抗感染藥物市場正在穩步成長。抗感染藥物在維護動物健康、確保食品安全和支持全球動物性蛋白質供應方面發揮關鍵作用。動物細菌、病毒和真菌感染的日益流行,使得牲畜和伴侶動物領域對先進的抗感染藥物的需求日益迫切。農民和寵物主人對及時獸醫護理重要性的認知不斷提高,進一步加速了抗生素、抗病毒藥物、抗真菌藥物和聯合療法的採用。為了滿足日益成長的肉類、牛奶和蛋類需求,商業化畜牧養殖的擴大更加凸顯了疾病控制的重要性,獸醫抗感染藥物已成為現代動物保健實踐中不可或缺的組成部分。

市場概覽
預測期 2026-2030
2024年市場規模 83.7億美元
2030年市場規模 122億美元
2025-2030 年複合年成長率 6.45%
成長最快的領域 抗病毒藥物
最大的市場 北美洲

市場成長動力包括人畜共通傳染病發病率的上升,這更凸顯了控制動物感染以保障公眾健康的重點。獸醫研發投入的不斷增加也推動了抗感染製劑的創新,包括長效注射劑、標靶給藥系統以及解決抗藥性問題的聯合療法。隨著生產者和寵物主人轉向降低治療成本和提高生產力的健康管理實踐,對預防性解決方案的需求日益成長。塑造市場的一個主要趨勢是向益生菌、植物性和免疫促效劑等抗生素替代品的轉變,這反映了全球對抗菌素抗藥性的擔憂。診斷技術的不斷進步也使得更快地檢測感染成為可能,這補充了抗感染藥物的有效使用,並支持了精準獸醫用藥。

市場面臨的挑戰可能會限制其未來幾年的潛力。新獸藥的高昂開發成本,加上嚴格的法規核准流程,往往會延遲產品的上市,並限制某些地區的可及性。對抗生素抗藥性的擔憂導致抗生素的使用受到更嚴格的限制,迫使製造商在平衡最終用戶的承受能力的同時,投資替代品。小規模畜牧養殖戶對正確使用抗感染藥物的認知不足,可能導致藥物濫用、療效降低和抗藥性風險增加。偏遠或低度開發地區的供應鏈限制也限制了關鍵藥物的及時取得。應對這些挑戰需要政府、製藥公司和獸醫服務提供者之間的協調努力,以提高意識,加強分銷網路,並加速更安全、永續的抗感染解決方案的創新。儘管存在這些障礙,但全球獸用抗感染藥物市場預計將在不斷成長的動物健康需求、不斷發展的醫療保健實踐以及獸醫治療學的持續進步的支持下繼續擴張。

關鍵市場促進因素

畜禽傳染病發生率上升

主要市場挑戰

抗生素抗藥性(AMR)問題日益受到關注

主要市場趨勢

擴大處方管道和數位銷售

目錄

第 1 章:產品概述

第2章:研究方法

第3章:執行摘要

第4章:顧客之聲

第5章:全球獸用抗感染藥物市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依動物類型(牲畜、伴侶動物)
    • 依產品(抗菌劑、抗真菌劑、抗病毒劑、抗寄生蟲劑、其他)
    • 依給藥途徑(口服、注射、外用)
    • 按配銷通路(醫院/診所藥房、零售藥房、電子商務)
    • 按公司分類(2024)
    • 按地區
  • 市場地圖

第6章:北美獸用抗感染藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美:國家分析
    • 美國
    • 墨西哥
    • 加拿大

第7章:歐洲獸用抗感染藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲:國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章:亞太地區獸用抗感染藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區:國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章:南美獸用抗感染藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲:國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章:中東和非洲獸用抗感染藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA:國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章:市場動態

  • 驅動程式
  • 挑戰

第 12 章:市場趨勢與發展

  • 合併與收購(如有)
  • 產品發布(如有)
  • 最新動態

第13章:干擾:衝突、流行病與貿易壁壘

第 14 章:波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 15 章:競爭格局

  • Zoetis Inc.
  • Boehringer Ingelheim Animal Health GmbH
  • Merck & Co., Inc.
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Ceva Sante Animale SA
  • Virbac SA
  • Biogenesis Bago SA
  • Vetoquinol SA
  • Norbrook Laboratories Limited

第 16 章:策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 30570

Global Veterinary Anti-infectives Market was valued at USD 8.37 Billion in 2024 and is expected to reach USD 12.20 Billion by 2030 with a CAGR of 6.45%. The Global Veterinary Anti-infectives Market is experiencing steady growth as livestock and companion animal populations continue to rise, driving greater demand for effective disease prevention and treatment solutions. Anti-infectives play a critical role in maintaining animal health, ensuring food safety, and supporting the global supply of animal-based proteins. The increasing prevalence of bacterial, viral, and fungal infections in animals is creating a strong need for advanced anti-infective medicines across both livestock and companion animal sectors. Growing awareness among farmers and pet owners about the importance of timely veterinary care has further accelerated the adoption of antibiotics, antivirals, antifungals, and combination therapies. Expanding commercial livestock farming to meet the rising demand for meat, milk, and eggs has amplified the importance of disease control, positioning veterinary anti-infectives as an indispensable component of modern animal healthcare practices.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 8.37 Billion
Market Size 2030USD 12.20 Billion
CAGR 2025-20306.45%
Fastest Growing SegmentAntivirals
Largest MarketNorth America

Growth drivers for the market include the rising incidence of zoonotic diseases, which has heightened the focus on controlling animal infections to safeguard public health. Increasing investments in veterinary research and development are also fueling innovation in anti-infective formulations, including long-acting injectables, targeted drug delivery systems, and combination therapies that address resistance issues. Demand for preventive solutions is gaining traction as producers and pet owners shift toward health management practices that reduce treatment costs and improve productivity. A major trend shaping the market is the transition toward antibiotic alternatives such as probiotics, phytogenics, and immunostimulants, reflecting global concerns about antimicrobial resistance. Continuous advancements in diagnostic technologies are also enabling faster detection of infections, which complements the effective use of anti-infectives and supports precision veterinary medicine.

The market faces challenges that could restrict its potential in the coming years. High development costs for new veterinary medicines, coupled with stringent regulatory approval processes, often delay product launches and limit accessibility in certain regions. Concerns around antimicrobial resistance are leading to stricter restrictions on antibiotic usage, pressuring manufacturers to invest in alternatives while balancing affordability for end users. Limited awareness among small-scale livestock farmers about the correct use of anti-infectives can result in misuse, reduced efficacy, and increased resistance risks. Supply chain limitations in remote or underdeveloped areas also restrict timely access to critical medicines. Addressing these challenges requires coordinated efforts between governments, pharmaceutical companies, and veterinary service providers to enhance awareness, strengthen distribution networks, and accelerate innovation in safer, sustainable anti-infective solutions. Despite these hurdles, the Global Veterinary Anti-infectives Market is expected to expand, supported by rising animal health needs, evolving healthcare practices, and ongoing advancements in veterinary therapeutics.

Key Market Drivers

Rising Incidence of Infectious Diseases in Livestock and Poultry

The rising incidence of infectious diseases in livestock and poultry is a significant driver of the Global Veterinary Anti-infectives Market. In the United States, the USDA reported processing over 9.4 billion broiler chickens and 218 million turkeys in 2023. This large-scale production increases the risk of disease outbreaks, necessitating effective anti-infective solutions to maintain animal health and productivity. Similarly, India, with the world's highest livestock population, including 300 million cattle and buffaloes and 851 million poultry, faces challenges in managing diseases among its vast animal population. The prevalence of diseases such as Foot and Mouth Disease and Lumpy Skin Disease in these regions underscores the need for robust veterinary anti-infective measures.

In China, the Ministry of Agriculture and Rural Affairs has been proactive in enhancing animal health surveillance and disease control programs to address the growing concerns of infectious diseases in livestock and poultry. The government's efforts to strengthen veterinary infrastructure and promote disease prevention strategies have contributed to the increased demand for veterinary anti-infectives. These initiatives aim to mitigate the impact of infectious diseases on animal health and ensure food security. The escalating incidence of infectious diseases in livestock and poultry across these regions highlights the critical need for effective veterinary anti-infectives to safeguard animal health and support the growth of the global veterinary anti-infectives market.

Key Market Challenges

Rising Concerns Over Antimicrobial Resistance (AMR)

Rising concerns over antimicrobial resistance (AMR) represent one of the most significant challenges for the Global Veterinary Anti-infectives Market, as the misuse and overuse of antibiotics in livestock and companion animals contribute to the development of drug-resistant pathogens. AMR poses serious threats not only to animal health but also to human health due to the potential transfer of resistant bacteria through the food chain, direct contact, or environmental contamination. Regulatory authorities worldwide are increasingly implementing stricter guidelines to limit antibiotic use in animals, including restrictions on growth-promoting antibiotics and tighter controls on prophylactic administration. These regulations create pressure on manufacturers and veterinarians to adopt alternative approaches to disease management, such as vaccines, immunostimulants, probiotics, and other non-antibiotic therapies, which may not always be as widely available or cost-effective as traditional anti-infectives.

The growing awareness of AMR among consumers, farmers, and healthcare professionals has intensified demand for responsible and judicious use of veterinary medicines. Pharmaceutical companies face the challenge of balancing the development of effective anti-infectives with compliance to evolving global standards while ensuring affordability for farmers, particularly in emerging markets where cost sensitivity is high. Research and development efforts to create next-generation therapies that are effective yet less prone to resistance are resource-intensive, requiring significant time and financial investment. Inadequate farmer education and poor adherence to dosing protocols can exacerbate resistance issues, further complicating disease management. The AMR challenge is reshaping treatment strategies and driving innovation in veterinary medicine, but it also imposes significant operational, regulatory, and economic pressures on the veterinary anti-infectives market, making it a critical hurdle for sustained growth and adoption.

Key Market Trends

Expansion of Prescription-Based Channels and Digital Sales

A key trend in the Global Veterinary Anti-infectives Market is the expansion of prescription-based channels and digital sales, which is reshaping how veterinary medicines are accessed and distributed. Increasing regulatory oversight on antimicrobial usage, aimed at combating antimicrobial resistance, has led many countries to restrict the availability of certain anti-infective drugs over the counter, prompting a shift toward prescription-only access. This transition ensures more controlled and responsible usage of antibiotics, antivirals, and antifungal medications, while improving adherence to dosage guidelines and reducing the risk of resistance development. Prescription-based channels also allow veterinarians to play a more active role in disease management, guiding producers and pet owners on the appropriate choice of therapy and monitoring treatment outcomes.

Simultaneously, digital sales platforms and e-commerce solutions are expanding the reach of veterinary anti-infectives to both urban and rural markets. Online pharmacies and veterinary supply platforms provide convenient access to a broad portfolio of medicines, particularly for farmers managing large herds or flocks where timely procurement is essential. Integration of digital tools with prescription channels enables better tracking of drug usage, inventory management, and compliance with veterinary guidelines. Telemedicine and virtual consultation services are also gaining traction, allowing veterinarians to diagnose, prescribe, and monitor treatments remotely, which is especially valuable in regions with limited veterinary infrastructure. The combination of stricter prescription regulations and the convenience of digital sales channels is transforming the market landscape, enhancing accessibility, supporting antibiotic stewardship programs, and encouraging data-driven decision-making in veterinary healthcare. This trend is expected to continue shaping the adoption and distribution of anti-infectives across livestock and companion animal segments globally.

Key Market Players

  • Zoetis Inc.
  • Boehringer Ingelheim Animal Health GmbH
  • Merck & Co., Inc.
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Ceva Sante Animale S.A.
  • Virbac S.A.
  • Biogenesis Bago S.A.
  • Vetoquinol S.A.
  • Norbrook Laboratories Limited

Report Scope:

In this report, the Global Veterinary Anti-infectives Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Veterinary Anti-infectives Market, By Animal Type:

  • Livestock Animal
  • Companion Animal

Veterinary Anti-infectives Market, By Product:

  • Antimicrobial
  • Antifungals
  • Antivirals
  • Antiparasitic
  • Others

Veterinary Anti-infectives Market, By Route of Administration:

  • Oral
  • Injectable
  • Topical

Veterinary Anti-infectives Market, By Distribution Channel:

  • Hospital/ Clinic Pharmacy
  • Retail Pharmacies
  • E-commerce

Veterinary Anti-infectives Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Anti-infectives Market.

Available Customizations:

Global Veterinary Anti-infectives Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Veterinary Anti-infectives Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Animal Type (Livestock Animal, Companion Animal)
    • 5.2.2. By Product (Antimicrobial, Antifungals, Antivirals, Antiparasitic, Others)
    • 5.2.3. By Route of Administration (Oral, Injectable, Topical)
    • 5.2.4. By Distribution Channel (Hospital/ Clinic Pharmacy, Retail Pharmacies, E-commerce)
    • 5.2.5. By Company (2024)
    • 5.2.6. By Region
  • 5.3. Market Map

6. North America Veterinary Anti-infectives Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Animal Type
    • 6.2.2. By Product
    • 6.2.3. By Route of Administration
    • 6.2.4. By Distribution Channel
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Veterinary Anti-infectives Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Animal Type
        • 6.3.1.2.2. By Product
        • 6.3.1.2.3. By Route of Administration
        • 6.3.1.2.4. By Distribution Channel
    • 6.3.2. Mexico Veterinary Anti-infectives Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Animal Type
        • 6.3.2.2.2. By Product
        • 6.3.2.2.3. By Route of Administration
        • 6.3.2.2.4. By Distribution Channel
    • 6.3.3. Canada Veterinary Anti-infectives Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Animal Type
        • 6.3.3.2.2. By Product
        • 6.3.3.2.3. By Route of Administration
        • 6.3.3.2.4. By Distribution Channel

7. Europe Veterinary Anti-infectives Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Animal Type
    • 7.2.2. By Product
    • 7.2.3. By Route of Administration
    • 7.2.4. By Distribution Channel
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Veterinary Anti-infectives Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Animal Type
        • 7.3.1.2.2. By Product
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By Distribution Channel
    • 7.3.2. Germany Veterinary Anti-infectives Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Animal Type
        • 7.3.2.2.2. By Product
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By Distribution Channel
    • 7.3.3. United Kingdom Veterinary Anti-infectives Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Animal Type
        • 7.3.3.2.2. By Product
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By Distribution Channel
    • 7.3.4. Italy Veterinary Anti-infectives Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Animal Type
        • 7.3.4.2.2. By Product
        • 7.3.4.2.3. By Route of Administration
        • 7.3.4.2.4. By Distribution Channel
    • 7.3.5. Spain Veterinary Anti-infectives Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Animal Type
        • 7.3.5.2.2. By Product
        • 7.3.5.2.3. By Route of Administration
        • 7.3.5.2.4. By Distribution Channel

8. Asia-Pacific Veterinary Anti-infectives Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Animal Type
    • 8.2.2. By Product
    • 8.2.3. By Route of Administration
    • 8.2.4. By Distribution Channel
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Veterinary Anti-infectives Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Animal Type
        • 8.3.1.2.2. By Product
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By Distribution Channel
    • 8.3.2. India Veterinary Anti-infectives Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Animal Type
        • 8.3.2.2.2. By Product
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By Distribution Channel
    • 8.3.3. South Korea Veterinary Anti-infectives Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Animal Type
        • 8.3.3.2.2. By Product
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By Distribution Channel
    • 8.3.4. Japan Veterinary Anti-infectives Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Animal Type
        • 8.3.4.2.2. By Product
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By Distribution Channel
    • 8.3.5. Australia Veterinary Anti-infectives Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Animal Type
        • 8.3.5.2.2. By Product
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By Distribution Channel

9. South America Veterinary Anti-infectives Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Animal Type
    • 9.2.2. By Product
    • 9.2.3. By Route of Administration
    • 9.2.4. By Distribution Channel
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Veterinary Anti-infectives Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Animal Type
        • 9.3.1.2.2. By Product
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By Distribution Channel
    • 9.3.2. Argentina Veterinary Anti-infectives Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Animal Type
        • 9.3.2.2.2. By Product
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By Distribution Channel
    • 9.3.3. Colombia Veterinary Anti-infectives Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Animal Type
        • 9.3.3.2.2. By Product
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By Distribution Channel

10. Middle East and Africa Veterinary Anti-infectives Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Animal Type
    • 10.2.2. By Product
    • 10.2.3. By Route of Administration
    • 10.2.4. By Distribution Channel
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Veterinary Anti-infectives Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Animal Type
        • 10.3.1.2.2. By Product
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By Distribution Channel
    • 10.3.2. Saudi Arabia Veterinary Anti-infectives Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Animal Type
        • 10.3.2.2.2. By Product
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By Distribution Channel
    • 10.3.3. UAE Veterinary Anti-infectives Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Animal Type
        • 10.3.3.2.2. By Product
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Disruptions: Conflicts, Pandemics and Trade Barriers

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Zoetis Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Boehringer Ingelheim Animal Health GmbH
  • 15.3. Merck & Co., Inc.
  • 15.4. Dechra Pharmaceuticals PLC
  • 15.5. Elanco Animal Health Incorporated
  • 15.6. Ceva Sante Animale S.A.
  • 15.7. Virbac S.A.
  • 15.8. Biogenesis Bago S.A.
  • 15.9. Vetoquinol S.A.
  • 15.10. Norbrook Laboratories Limited

16. Strategic Recommendations

17. About Us & Disclaimer